Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Value of Revaccinating People with MM After aHCT

Biol Blood Marrow Transplant; ePub 2017 Dec 27; Palazzo, et al

Using inactive vaccine to re-immunizing autologous hematopoietic stem cell transplant (aHCT) recipients receiving lenalidomide maintenance (LM) is safe and effective, according to a study involving 122 individuals. Participants had multiple myeloma and were vaccinated after aHCT between 2010 and 2014 at a single center. Investigators looked at vaccination safety and efficacy. Among the results:

  • Three-fourths of patients were receiving LM.
  • Vaccine responses differed by vaccine type; 76% responded to pertussis, 70% diphtheria, 60% tetanus, 71% haemophilus influenzae, and 58% pneumococcal.
  • All patients retained polio immunity; 27% responded with increased titers.
  • 3 in every 10 patients who received the hepatitis A vaccine responded; 4 in every 10 who received the hepatitis B vaccine did so.
  • Response rates were similar in patients who received or did not receive LM.
  • There were no vaccine related adverse effects.

Citation:

Palazzo M, Shah G, Copelan B, et al. Re-Vaccination following autologous hematopoietic stem cell transplantation is safe and effective in patients with multiple myeloma receiving lenalidomide maintenance. [Published online ahead of print December 27, 2017]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2017.12.795.